PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans-Reference-Cited by-同舟云学术

PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans

Published:2017-07-31 Issue:17 Volume:24 Page:1870-1877
ISSN:2047-4873
Container-title:European Journal of Preventive Cardiology
language:en
Short-container-title:Eur J Prev Cardiolog

Author:

Baragetti Andrea¹²,Balzarotti Gloria¹,Grigore Liliana²³,Pellegatta Fabio²³,Guerrini Uliano¹,Pisano Giuseppina⁴,Fracanzani Anna L⁴,Fargion Silvia⁴,Norata Giuseppe D¹⁵,Catapano Alberico L¹³

Affiliation:

1. Department of Pharmacological and Biomolecular Sciences, Università degli Studi di Milano, Italy

2. SISA Center for the Study of Atherosclerosis, Bassini Hospital, Italy

3. IRCCS Multimedica Hospital, Italy

4. Department of Pathophysiology and Transplantation, Ca’ Granda Foundation IRCCS Maggiore Policlinico Hospital, Università degli Studi di Milano, Italy

5. School of Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Western Australia

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine,Epidemiology

Link

http://journals.sagepub.com/doi/pdf/10.1177/2047487317724342

Reference44 articles.

1. The PCSK9 decade

2. PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia

3. Sequence Variations inPCSK9,Low LDL, and Protection against Coronary Heart Disease

4. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

5. Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE- and LDLR-mediated mechanisms

Cited by 59 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Proprotein convertase subtilisin/kexin type 9 deficiency in extrahepatic tissues: emerging considerations;Frontiers in Pharmacology;2024-07-30

2. The role of PCSK9 in metabolic dysfunction-associated steatotic liver disease and its impact on bariatric surgery outcomes;Surgery for Obesity and Related Diseases;2024-07

3. PCSK9 and Lipid Metabolism: Genetic Variants, Current Therapies, and Cardiovascular Outcomes;Cardiovascular Drugs and Therapy;2024-06-22

4. A promising therapy for fatty liver disease: PCSK9 inhibitors;Phytomedicine;2024-06

5. Metabolic dysfunction-associated steatotic liver disease: An opportunity for collaboration between cardiology and hepatology;Atherosclerosis;2024-05